Retention and expansion for Series B companies: scaling without breaking for healthcare and life sciences in Southern Europe
How Series B companies scale retention and expansion across regions and teams without losing the discipline that made it work at Series A. Written for commercial leaders at healthtech, medtech, and life-sciences companies in Southern Europe.
This edition of the Growth Broker playbook is written for commercial leaders at healthtech, medtech, and life-sciences companies operating in Southern Europe. In this market, Southern European buyers reward relationship depth over transactional outreach, so the way you install retention and expansion has to be shaped to that reality from day one.
Series B is the stress test for retention and expansion. What worked at fifteen people fails at fifty unless the operating rhythm is deliberate.
The Series B move is to separate the model owner from the operators. One senior human owns strategy, gross and net revenue retention, and the weekly review; a small team runs the machine.
Add a second geography or segment only when the first one is producing a defensible number for two full quarters. Not before.
Inside healthcare and life sciences, the binding constraint is almost always regulated-sale cycle length, not intent, and in Southern Europe it is compounded by the fact that relationship depth, not activity volume is what actually gates growth. Retention and expansion is only useful here when it is pointed at both constraints at once.
Governance appears at Series B — that is fine, provided it accelerates rather than slows. The test is whether reviews still make decisions or just distribute updates.
The Series B failure mode of retention and expansion is treating CS as a support cost centre, amplified by headcount. Fix the root cause; do not paper over it with more people.
Compensation begins to matter now. Pay operators on gross and net revenue retention outcomes, not on effort. Effort-based comp at Series B produces theatre.
A well-run retention and expansion function at Series B is the moat that survives to Series C. Companies that skip this discipline burn through raises trying to buy it back.
Concretely for healthcare and life sciences in Southern Europe: the healthcare teams that install this get past procurement instead of dying in it, and a single trusted Southern European relationship compounds into a regional beachhead. That is the reason it is worth installing retention and expansion deliberately for this market rather than importing a playbook designed for somewhere else.
Frequently asked questions
Retention · healthcare · Southern Europe — answered
- Does retention and expansion work for healthcare and life sciences in Southern Europe?
- Yes — provided it is pointed at regulated-sale cycle length, not intent and adapted to the fact that in Southern Europe, Southern European buyers reward relationship depth over transactional outreach. The healthcare teams that install this get past procurement instead of dying in it.
- How does retention and expansion change at Series B?
- Ownership separates from execution; operating rhythm gets more deliberate; governance appears.
- When should we expand to a second region?
- After the first region delivers two straight quarters of defensible gross and net revenue retention.
- What compensation model works for retention and expansion operators at Series B?
- Outcome-linked on gross and net revenue retention, not activity-based.
- What is the Series B stress point?
- Treating CS as a support cost centre, amplified by headcount. Fix the root, not the symptom.
- What is the Southern Europe-specific pitfall when running retention and expansion for healthcare?
- Importing a playbook that was built for another market. In Southern Europe, Southern European buyers reward relationship depth over transactional outreach — the install has to reflect that.
Growth Broker editorial
Filed under retention · healthcare · southern europe